Home

BESTAGRO — Deck

Best Agrolife · BESTAGRO · NSE/BSE

Best Agrolife is India's #13 agrochemical formulator, selling patented and generic crop-protection products through roughly 10,900 dealers; about two-thirds of revenue is branded and one-third bulk institutional.

$0.19
Price
$67M
Market cap
$191M
Revenue (TTM)
525+
Formulation registrations
Listed 2016 as Sahyog Multibase; rebranded as Best Agrolife and ran from ~$0.41 in early 2021 to ~$1.43 by Dec-2022 on the Ronfen patent launch; now $0.19 after an 85% drawdown, a 1-for-10 split and a 1-for-2 bonus. Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins and multiples are unitless and unchanged.
2 · The binary

The entire bull-bear debate collapses to one auditor's signature, due in 28 days.

  • 30 May 2026. The FY26 audited annual report is due under SEBI LODR Reg 33 — the new auditor's first opinion on this company. Until that disclosure lands, every other data point on the page supports both readings.
  • Bull's path to $0.37. A clean opinion plus inventory days under 300 plus CFO/NI above 0.7 re-rates the equity to roughly 1.5× book — Insecticides India's peer multiple, with the forensic discount lifted.
  • Bear's path to $0.11. Any qualification, key-audit-matter on inventory or related parties, or going-concern note opens the path to a ~$42M write-down — book collapses from $0.24 to ~$0.11 a share, the level the March-2026 $0.13 low briefly pretended to.
Position before the print, not after. The disclosure that resolves the thesis lands inside 30 trading days, and there is no sell-side coverage to front-run.
3 · The number that breaks the model

Inventory was 67 days in FY22. It is 864 days in FY25. Pick a story.

864
Inventory days FY25 from 67 in FY22
−0.43
Cumulative CFO/NI FY22–FY25 ($52M NI, −$23M cash)
521
Payable days FY25 suppliers funded the build
−25%
Borrowings H1 FY26 $67M → $50M in 6 months

Four years of reported earnings (~$52M) generated negative cash (−$23M) — no peer in listed Indian agrochem has a comparable disconnect; even UPL converts at roughly 1×. The build was financed by stretching suppliers from 72 to 521 days. The bull reads the H1 FY26 ~$17M borrowings drawdown — at a 32% gross margin held in the trough quarter — as proof the inventory is real and converting. The bear reads it as saleable stock liquidating first while ~$42M of impaired residue still carries at cost. The audited FY26 inventory-days line decides which.

4 · Two businesses, opposite trajectories

Patented sales fell 5%; generics fell 48%. The market is pricing both at zero.

  • The split is in the disclosure. 9M FY26: patented portfolio (Ronfen, Tricolor, Defender, Orisulam — ~$42M in FY25) declined 5% YoY; the rest of the book fell 48%. Q3 FY26 gross margin held at 32% on revenue down 31% — pull-driven economics, not push-driven distress.
  • The patented share went from zero to 30%. Eight launches in three years on the back of CIB&RC 9(3)/9(4) registrations and in-house Diafenthiuron synthesis — the only category management has reliably hit while missing every revenue and margin guide.
  • The arithmetic is uncomfortable. Apply Dhanuka's 4× sales to the ~$42M patented book alone and you get ~$148M — more than the entire $67M equity market cap. The bulk business is being valued at less than zero.
If Ronfen is 70% of the patented book, this is single-product optionality. If Bestman and Fetagen each scale past $5M in FY27, it is a real franchise at a third of Dhanuka's multiple.
5 · The bench thinned at the worst moment

Two directors, the statutory auditor, and the company secretary all walked between July and October 2025.

  • Cluster of exits. 2 Jul 2025: two directors resigned the same day with no public reason — one an executive WTD on ~$230k, the other the chair of the Stakeholder Relationship Committee. 14 Aug 2025: Walker Chandiok resigned as statutory auditor. October 2025: the Company Secretary followed.
  • Foreign money agreed. FII ownership halved from 10.84% (Q2 FY24) to 5.63% (FY26) over the same drawdown. Only one mutual fund (Quant Small Cap, 0.04% AUM) sits on the register. Retail base doubled into the fall — the wrong direction for institutional discovery.
  • The founder is the offsetting fact. He owns 47.95% personally, 50.44% with the group, zero pledge, zero selling — and personally subscribed ~$4M of warrants at $7.48 (effective ~$0.49 post split-and-bonus) when the spot was already $0.19. Walker Chandiok signed FY25 unqualified before resigning; auditors who object to client accounting almost always resign before signing, not three months after.
Three governance touchstones — board, auditor, compliance officer — turned over inside one fiscal quarter. The check on the founder is paper-thin, and the people who would normally provide it have walked.
6 · Bull and Bear

No edge today — the single most decisive disclosure prints inside 30 days. Wait for it.

  • For. The patented engine held at −5% while generics fell 48%, gross margin printed 32% in the trough, and 8 of 8 patented launches have shipped — pricing power is real, even if small.
  • For. Borrowings drained ~$17M in six months at full gross margin — inconsistent with the 30% inventory haircut that the 0.79× P/B is partly pricing. The founder owns 50% un-pledged and personally paid ~$4M at ~35× the spot.
  • Against. ~$52M of reported FY22–FY25 PAT generated −$23M of operating cash — the four-year gap is paid for either by the 864-day inventory or by a write-down. Both cannot be true.
  • Against. Cluster of senior departures Jul–Oct 2025; ADV at 0.025% of market cap means even a correct fundamental call has no marginal institutional buyer. The discount can persist regardless of whether it should.
My view — no edge. Lean long if FY26 audit prints clean with inventory days under 300 and the ~$12M warrant balance is paid by 27 June. Lean short on any KAM, emphasis-of-matter, or going-concern note from the new auditor.

Watchlist to re-rate: FY26 audit opinion + balance-sheet inventory days (by 30 May 2026); ~$12M warrant balance pay-or-forfeit (27 June 2026); IMD monsoon bulletins June–September; Bestman and Fetagen revenue scale-up in the FY26 segment disclosure.